Aspen Explains Logic Behind €642m Mylan Thrombosis Deal
Transaction Forms Part Of Company Overhaul
Aspen Pharmacare last week announced the sale of its thrombosis business in Europe to Mylan for €642m ($762m). CEO Stephen Saad faced investors to detail the rationale for the US firm and what the planned transaction means for Aspen, including its material debt pile.
You may also be interested in...
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.